Reinduction with lapatinib followed by retreatment with trastuzumab-based therapy after disease progression multi-HER2 targeted therapies in HER2-positive metastatic breast cancer
Not Applicable
- Conditions
- HER2-positive metastatic breast cancer
- Registration Number
- JPRN-UMIN000014189
- Lead Sponsor
- JFCR Breast Med Oncol
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
1) active synchuronous cancer 2) active infectious disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CBR
- Secondary Outcome Measures
Name Time Method